Project Grant R21AG091064
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $492K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $162,486.00 to support research on the role of regulatory T cells in Alzheimer's disease (AD). The grant was awarded to the Regents of the University of Minnesota, Office of Sponsored Projects Administration on November 16, 2024, with an ultimate completion date of July 31, 2027. The project aims to advance scientific understanding of the relationship between regulatory T cells and the...
- This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $704,198.00 to Trustees of Dartmouth College from December 1, 2024 to November 30, 2026 to develop chimeric antigen receptor (CAR) T regulatory cells (Tregs) that target aggregated amyloid-beta, a key hallmark of Alzheimer's disease (AD). The goal is to enhance the persistence of these CAR Tregs in the central nervous system to help rebalance cerebral immunity, promote amyloid-beta...
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
- The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $167,940 project grant to The Children's Hospital Corporation (Boston Children's Hospital) to elucidate the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease. The project, awarded on August 15, 2025, aims to (1) determine if the MEF2 transcription factors mediate survival of specific neuronal subtypes vulnerable to Alzheimer's pathology, (2) assess whether...
- The Brigham & Women's Hospital Inc. was awarded a $3,672,952 Project Grant from the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) to investigate the role of tRNA-derived fragments (TRFs) in tau pathology associated with Alzheimer's disease (AD) and related tauopathies. The research aims to characterize the small RNA landscape, with a focus on TRFs, at different stages of AD pathology and examine the RNA binding capacity of tau variants. The...
- This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
- This Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The goal of the project is to test whether a new humanized monoclonal antibody (ADWA11) can restore microglia-astrocyte responses as a therapy for Alzheimer's disease (AD). The $254,896 award to Glial Therapeutics, LLC will support research to understand how pharmacological inhibition of the ITGB8 integrin can modulate microglia phenotype and function to...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,173,794 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing brain resilience to Alzheimer's disease by targeting adult hippocampal neurogenesis. The project aims to explore the mechanisms by which adult hippocampal neurogenesis cooperates with brain-derived neurotrophic factor (BDNF) to potentially slow cognitive decline in...